TISSUE FACTOR - KUNITZ DOMAIN FUSION PROTEINS AS FACTOR VIIa INHIBITORS

Abstract: The invention provides compositions having a Factor VIIa active site inhibitor domain and a tissue factor domain for the inhibition of FVIIa. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.

Description: TISSUE FACTOR - KUNITZ DOMAIN FUSION PROTEINS AS FACTOR Vi la INHIBITORS Field of the Invention This invention relates to novel compositions which bind to and inhibit an activity associated w ith plasma Factor Vll Factor Vila Specifically, the mvention provides molecules havmg a Factor Vila active site inhibitor domam and a tissue factor domam Accordmg to a preferred aspect, the two domains ofthe hybrid molecule of the present invention are linked via flexible peptide linker domain The mvention also relates to pharmaceutical compositions compnsmg the novel compositions as well as their use m diagnostic therapeutic, and prophylactic methods Description of Related Disclosures Factor Vila (FVIIa) is a two-chain, 50 kilodalton (kDa), vitamin K-dependent, plasma serine protease which participates in the complex regulation of in vivo hemostasis Factor Vila is generated by proteolysis of a single peptide bond from its single chain zymogen, Factor VII, which is present at approximateh 0 5 μg/ml in plasma The conversion of zymogen Factor VII mto the activated two-chain molecule occurs by cleavage of an internal peptide bond In human Factor VII, the cleavage site is at Argl52-Ilel53 (Hagen et al , (1986) Proc Natl Acad Sci USA 83 2412-2416, Thim et al , (1988) Biochem 27 7785-7793,) In the presence of calcium ions, Factor Vila binds with high affinity to tissue factor (TF), an mtegral membrane protein TF is a cofactor for Factor Vila, enhancing the proteolytic activation of its substrates Factors VII (FVII), Factor IX (FIX) and Factor X (FX) TF is a 263 am o acid residue glycoprotein composed of a 219 residue extracellular domam, a single transmembrane domain, and a short cytoplasmic domam (Momssey, J H , et al , (1987) 50 129) The TF extracellular domam is composed of two fibronectin type III domains of about 105 ammo acids each The binding of FVIIa is mediated entirely by the TF extracellular domam (Muller et al , (1994) Biochem 33 10864- 10870, Gibbs et al , (1994) Biochem 33 14003-14010, Ruf et al , (1994) Biochem 33 1565-1572) The structure ofthe TF extracellular domam has recently been determined by x-ray crystallography (Harlos et al , (1994) Nature 370 662-666, Muller et al , (1994) Biochemistry 33 10864) The TF extracellular domam has also has been extensively characterized by alanine scanning mutagenesis (Kelley et al , (1995) Biochemistry, 34 10383-10392, Gibbs et al , (1994) supra. Ruf et al , (1994) supra) Residues in the area of ammo acids 16-26 and 129-147 contribute to the binding of FVIIa as well as the coagulant function of the molecule Residues Lys20, Trp45, Asp58, Tyτ94, and Phel40 make a large contribution (1 kcal/mol) to the free energy (ΔG) of binding to FVIIa (Kelley et al , (1995) supra) Residues in the area of ammo acids 157-168 contribute to the procoagulant function of TF-FVIIa (Kelley et al , (1995) supra. Ruf et al , (1992) J Biol Chem 267 22206-22210) but are not important for FVII/FVIIa binding It has been shown that lysine residues 165 and 166 are important to TF cofactor function but do not participate in FVIIa complex formation (Roy et al , (1991) J Biol Chem 266 22063 Ruf et al , (1992) J Biol Chem 267 6375) Alanine substitution of these lysine residues results in a decreased rate of FX activation catalyzed by the TF-FVIIa complex (Ruf et al , (1992) supra) Lysine residues 165 and 166 are located on the C-terminal fibronectin type III domain of TF on the opposite surface ofthe molecule from residues found to be important for FVIIa binding on the basis of mutagenesis results (Kellev et al (1995) supra) A set of residues Trpl58, Lysl59, Serl63, Glyl64 Lys 165, Lys 166, and Tyrl 85 play a role the coagulant function of soluble TF but do not participate in FVIIa binding (Kelley et al , (1995) supra) TF is expressed constitutively on cells separated from plasma by the vascular endothelium (Carson, S D and J P Brozna, (1993) Blood Coag Fibπnol 4 281-292) Its expression on endothelial cells and monocytes is induced by exposure to inflammatory cytokines or bacterial lipopolysaccharides (Drake et al , (1989) J Cell Biol 109 389) Upon tissue injury, the exposed extracellular domain of TF forms a high affinitv calcium dependent complex with FVII Once bound to TF FVII can be activated by peptide bond cleavage to yield serine protease FVIIa The enzyme that catalyzes this step vivo has not been elucidated, but vitro FXa, thrombm TF-FVIIa and FlXa can catalyze this cleavage (Davie, et al , (1991) 30 10363-10370) FVIIa has only weak activity upon its physiological substrates FX and FFX whereas the TF-FVIIa complex rapidly activates FX and FIX The TF-FVIIa complex constitutes the primary initiator of the extrinsic pathway of blood coagulation (Carson, S D and Brozna, J P , (1993) Blood Coag Fibπnol 4 281-292, Davie, E W et al (1991) Biochemistry 30 10363-10370, Rapaport, S I and L V M Rao, ( 1992) Arteπoscler Thromb 12 1 1 1 1 - 1 121 ) The complex initiates the extrinsic pathway by activation of FX to Factor Xa (FXa), FIX to Factor IXa (FIXa), and additional FVII to FVIIa The action of TF-FVIIa leads ultimately to the conversion of prothrombin to thrombm, which carries out many biological functions (Badimon, L et al , (1991) Trends Cardiovasc Med 1 261-267) Among the most important functions of thrombm is the conversion of fibrinogen to fibrin, which polymerizes to form a clot The TF-FVIIa complex also participates as a secondary factor in extending the physiological effects ofthe contact activation system The involvement of this plasma protease system has been suggested to play a significant role in a vanety of clinical manifestations mcludmg arterial and venous thrombosis, septic shock, adult respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC) and various other disease states (Haskel, E J et al , (1991) Circulation 84 821-827), Hoist, J et al , (1993) Haemostasis 23 (suppl 1) 1 12- 1 17, Creasey, A A et al , (1993) J Clin Invest 91 2850-2860, see also, Colman R W (1989) N Engl J Med 320 1207-1209, Bone, R C (1992) Arch Intern Med 152.1381-1389) Overexpression and/or aberrant utilization of TF has been linked to the pathophysiology of both thrombosis and sepsis (Taylor et al , (1991 ) Circ Shock 33 127, Warr et al , (1990), Blood 75 1481 , Pawashe et al , (1994) Circ Res 74 56) TF is expressed on cells found in the atherosclerotic plaque (Wilcox et al , (1989) Proc Natl Acad Sci U S A 86 2839) Additionally, TF has been implicated in tumor metastasis (Bromberg et al , (1995) Proc Natl Acad Sci , USA, 92 8205) The presence in serum of an endogenous inhibitor of TF-FVIIa has long been recognized (Schneider, C L , (1946) Am J Physiol 149 123) Followmg initiation of the coagulation cascade, TF-FVIIa is regulated by tissue factor pathway inhibitor (TFPI), a feedback inhibitor that prevents further activation of zymogen substrates (Broze Jr , G J et al , (1990) Biochemistry 29 7539-7546, Broze Jr , G J , (1992) Semm Hematol 29 159-169) TFPI is also known as LACI or EPI for hpoprotein associated coagulation inhibitor and extrinsic pathway inhibitor, respectively TFPI contams an acidic ammo terminal region followed by three Kunitz-type domains and a basic carboxyl terminal region TFPI is thought to inhibit TF-FVIIa in a FXa dependent manner, first binding FXa via the second Kunitz domam followed by binding FVIIa via the first Kunitz domain (Girard, T J (1989) et al , Nature 338 518-520) In the absence of FXa, TFPI is a poor inhibitor of the TF-FVIIa complex (Girard, T J (1 90) et al , Science 248 1421-1424) Variants of TFPI have been made that also inhibit TF-FVIIa activity A variant that contams the first two Kunitz doma s (residues 1-161) has been made and characterized (Hamamoto et al (1993) J Biol Chem 268 8704-8710, Petersen et al (1993) J Biol Chem 268 13344-13351) Internationai Publication No WO 91/02753 as well as U S Patent 5,312,736 describe TFPI variants that retain their seπne protease inhibitory activity but have a decreased binding affinity for heparin A TFPI-FXa hybπd protein is able to inhibit TF-FVIIa induced coagulation of normal plasma in an in vitro coagulation assay with a greater activity than TFPI alone (Girard et al , ( 1990) Nature 248 1421 - 1424) TFPI and variants have been shown to affect hemostasis m animal models of arterial reocclusion after thrombolysis (Haskel, E J et al , (1991) Circulation 84 821-827), venous thrombosis (Hoist, J et al , (1993) Haemostasis 23 (suppl 1) 112-117), and dissemmated intravascular coagulation resulting from septic shock (Creasey, A A et al , (1993) J Clin Invest 91 2850-2860) However, TFPI may not have all of the properties desired for an anticoagulant agent for the treatment of thrombotic disease Recently, the serpin antithrombin III (ATIII) has also been shown to inhibit TF-FVIIa activity in the presence of heparin (Rao, L V M et al , (1993) Blood 81 2600-2607, Lawson, J H (1993) et al , J Biol Chem 268 767-770, Broze Jr , G J et al , (1993) Blood 82 1679-1680, Mann, K G , (1993) Blood 82 1680-1681) Inhibition of TF-FVIIa by TFPI is reversible, whereas inhibition by ATIII is essentially irreversible The relative importance of ATIII hepann inhibition of TF-FVIIa versus TFPI m vivo is unknown Bov e pancreatic trypsin inhibitor (BPTI), also referred to as aprotinin, has recently been shown to competitively inhibit TF-FVIIa activity, albeit with relatively weak affinity (K, = 30 μM) (Chabbat J et al , ( 1993) Thromb Res 71 205-215) In addttion, BPTI has recently been shown to inhibit TF-induced coagulation, however, ca 75 μM was needed to prolong the clotting time 1 4-fold m a PT assay (van den Besselaar, A M H P et al , (1993) Thromb Haemostas 69 298-299) Recently, the Kunitz domam of Alzheimer's amyloid β-protein precursor (APPI), which is structurally similar to BPTI (Hynes, T , et al , (1990) Biochemistry 29 10018-10022), was used as a scaffold for phage display of a large library of variants to select potent and specific active site mhibitors of tissue factor-Factor Vila (Dennis, M S , and Lazarus, R A , (1994) J Biol Chem 269 22129-22136, Dennis M S , and Lazarus, R A , (1994)J Biol Chem 269 22137-22144) Intemational Publication No WO 95/23860 describes the generation of Kunitz-type inhibitors of Factor Vila The foregoing FVIIa inhibitors have been classified as Kunitz-type ser e protease inhibitors (TFPI, BPTI, APPI, for example) Kunitz-type seπne protease inhibitors are a well charactenzed family of protems that exhibit extensive structural homology including a characteπstic tertiary fold containing an extended binding loop that fits mto the active site ofthe cognate serine protease (Bode, W , and Huber, R , (1992) Eur J Biochem 204 433-451 ) Kunitz-type seπne protease inhibitors are known to be slow, tight-binding, reversible inhibitors of serine proteases such as FVIIa that bmd to the active site and inhibit accordmg to the standard mechanism (Laskowski, Jr , M and Kato, I , ( 1980) Ann Rev Biochem 49 593-626) In a Kunitz-type domain/seπne protease complex, the side cham of residue 15 of the Kunitz-type domain fills the P j position preceding the scissile peptide bond The P j residue refers to the position preceding the scissile peptide bond ofthe substrate or inhibitor and fits mto the S | binding site as defined by Schecter and Berger (1967) Biochem Biophys Res Commun., 27 157-162. Cleavage between the P j and P,' residues occurs very slowly if at all (Bode, W and Huber, R., (1992) Eur J. Biochem 204-433-451 , Laskowski, M . Jr and Kato, I., (1980) Annu Rev Biochem. 49:593-626) Ofthe many interactions between the senne protease subsites and the side chains in the pπmary binding loop of Kunitz-type domain serine protease inhibitors (P5-P4 ) (Bode, W and Huber, R., ( 1992) Eur J Biochem 204433-451, Laskowski, M., Jr. and Kato, I., (1980) Annu Rev. Biochem. 49 593-626), the interactions ofthe Pi residue with the specificity pocket are energetically most important and therefore represent the primary specificity determinants Although the ammo acid at the P ] position generally dominates the affinity of inhibitors for the seπne protease active site (Scott, C. F. et al., (1987) Blood 69 1431-1436, Laskowski, M , Jr and Kato, I.. (1980) supra: Beckmann. J et al., (1988) Eur J Biochem. 176.675-682, Sinha, S et al , (1991) J Biol Chem 266:2101 1-21013), residues outside this region (1 1-14 and 16-19 as well as residue 34 of secondary binding loop) are also known to play a role in binding affinity and specificity towards senne proteases (Kossiakoff, A A et al., (1993) Biochem. Soc. Trans. 21 614-618); Roberts, B L. et al., (1992) Proc Natl Acad Sci USA 89 2429-2433) The crystal structures of Kunitz-type domains reveal residues within the pπmary binding loop that are likely to make contact with the serine protease (Hynes, T. R. et al., ( 1990) supra. Bode. W and Huber, R , (1992) su ra; Kossiakoff, A A. (1993), supra). Antagonists to tissue factor have also been demonstrated Neutralizing anti-TF monoclonal antibodies have been shown to prevent death in a baboon model of sepsis (Taylor et al., (1991) Circ Shock 33.127), attenuate endotoxin- induced DIC in rabbits (Warr et al., (1990), Blood 75.1481), and to prevent thrombus reformation in a rabbit model of arterial thrombosis (Pawashe et al., (1994) Circ Res 74:56) Incoφoration of lysine to alanine mutations at ammo acid residues 165 and 166 of soluble tissue factor results in a molecule that binds FVIIa with an affinity comparable to wild type soluble tissue factor (Kelley et al., (1995) supra). TF residues Lys 165 and Lys 166 have been shown to be important for inhibition of TF-FVIIa by the TFPI-FXa complex (Rao and Ruf, (1995) Biochemistry 34 10867-10871). The rate of inhibition by TFPI-FXa is decreased for FVIIa in complex with a TF mutant containing Lys to Ala substitutions at positions 165 and 166 as compared to FVIIa in complex with wild-type TF. Vanants of tissue factor have also been produced that bind to functional FVIIa but which have decreased procoagulant activity (International Publication No WO 94/28017) These molecules inactivate the cofactor activity of tissue factor in the TF-FVIIa complex but do not alter the ability of the molecule to complex FVIIa. Summary of the Invention The present invention provides compositions which inhibit a TF-FVIIa mediated or associated process such as the catalytic conversion of FVII to FVIIa, FIX to FIXa, or FX to FXa and thereby block initial events ofthe extπnsic pathway of blood coagulation. In addition, the compositions ofthe present mvention are capable of neutralizing the thrombotic effects of endogenous tissue factor by competing with endogenous tissue factor for bmdmg to FVII or FVIIa. Advantageously, the compositions allow for a potent inhibition ofthe TF-FVIIa complex providing, in preferred embodiments, for low dose pharmaceutical formulations The compositions of the present invention are useful in therapeutic and prophylactic methods for inhibiting TF-FVlla mediated or associated processes The compositions of the present mvention comprise a FVIIa active site inhibitor domain and a TF domam Accordmg to a preferred aspect ofthe present invention, the TF domain competes with endogenous TF for binding to FVII/FVIIa but has a decreased ability to act as a cofactor for the conversion of FVII to FVIIa, FIX to FTXa or FX to FXa The FVIIa active site inhibitor domam ofthe compositions of the present invention bmds to the seπne protease active site of FVIIa and prevents catalytic activation of its zymogen substrates In a preferred embodiment the active site inhibitor domam of the composition of the present invention is a reversible active site serme protease inhibitor molecule According to certain preferred aspects of the present invention the compositions further comprise a linker domain located between the FVIIa active site inhibitor domam and the TF domam The linker domain is preferably a hydrophilic flexible domam comprising a -(Gly) 4 -Ser- linker module In one embodiment, the composition of the present mvention is a polypeptide and the invention encompasses a composition of matter compnsmg an isolated nucleic acid, preferably DNA, encoding the polypeptide of the invention According to this aspect, the mvention further comprises an expression control sequence operably linked to the D A molecule, an expression vector, preferably a plasmid, compnsmg the DNA molecule, where the control sequence is recognized by a host cell transformed with the vector, and a host cell transformed with the vector The composition of the present invention may be made by a process which includes the steps of isolating or synthesizing nucleic acid sequences encoding any ofthe ammo acid sequences of the invention, ligating the nucleic acid sequence into a suitable expression vector capable of expressing the nucleic acid sequence in a suitable host, transforming the host with the expression vector mto which the nucleic acid sequence has been ligated, and cultuπng the host under conditions suitable for expression ofthe nucleic acid sequence, whereby the protein encoded by the selected nucleic acid sequence is expressed by the host Preferably, the polypeptide is then recovered from the host cell culture In this process the ligating step may further contemplate ligating the nucleic acid into a suitable expression vector such that the nucleic acid is operablv linked to a suitable secretory signal, whereby the ammo acid sequence is secreted by the host The secretory signal may be selected from the group consistmg ofthe leader sequence, for example, of stll, lamB, heφes gD, Ipp, alkaline phosphatase, invertase, and alpha factor and is preferably stll The present mvention further extends to therapeutic applications for the compositions descnbed herein Thus the mvention mcludes a pharmaceutical composition comprising a pharmaceutically acceptable excipient and the composition ofthe mvention Pharmaceutical compositions compnsmg these molecules can be used in the treatment or prophylaxis of thrombotic or coagulopathic related diseases or disorders including vascular diseases and inflammatory responses These applications mclude, for example, a method of treating a mammal for which inhibiting TF-FVIIa is mdicated compnsmg administermg a pharmaceutically effective amount ofthe pharmaceutical composition to the mammal Such indications include, deep venous thrombosis arterial thrombosis, post surgical thrombosis, coronary artery bypass graft (CABG), percutaneous transdermal coronary angioplasty (PTCA), stroke, tumor metastasis, inflammation, septic shock, hypotension, ARDS, and DIC The compositions ofthe present invention may also be used as an adjunct in thrombolytic therapy Brief Description of the Drawings Figure 1 depicts a schematic outline of selected enzymes and mediators that modulate the coagulation, contact, fibπnolytic, inflammatory, and complement pathways Activation of these pathways can lead to the clinical states indicated Figure 2 depicts a model of an exemplary composition The composition comprises a fusion protein having a TF domam, an active site inhibitor domain (APPI), and a linker domam The structure of TF determined at 2 4 A resolution (Muller et al , (1994) supra) was used for the TF portion ofthe molecule The Kunitz-type domain is based upon the structure determmed for APPI (Hynes et al , (1990) supra) A 22 residue polypeptide linker was modeled in extended conformation to connect the C-terminus of the Kunitz-domain to the N-terminus of TF The distance between these termini is about 60 A The C-terminus of TF is at the bottom ofthe molecule Figure 3 depicts a schematic diagram ofthe construction ofthe fusion gene for the bacteπal expression of a representative hybπd protein composition Only the fusion gene and promotor regions of the plasmid are shown The fusion genes were constructed by ligating the Pst/BamH 1 fragment encoding the TF7I-C Kunitz-type domain with pZTFAA and oligonucleotides prepared by chemical synthesis Figure 4 depicts a rendering of a representative polyacrylamide gel showing samples obtained from the various purification steps for a representative hybrid molecule mcludmg freeze-thawing, then osmotically shocking, cells to obtain a penplasmic shockate (lane 1), lmmunoaffmity chromatography usmg D3 monoclonal anti-tissue factor antibody to isolate TF-containing protems (lane 2), followed by size exclusion chromatography to remove high molecular weight species (lane 3) Figure 5 depicts the effect of fusion protems with 1 to 6 linker modules (KDTF1-KDTF6) on TF-FVIIa- dependant FX activation Fusion protein inhibition of TF-FVIIa mteractions was quantified in a FX activation assay The assay was performed by incubating 100 pM FVIIa with 1 nM inhibitor in TBS, pH 7 5, containing 5 mM CaCl 2 for 1 hr, then addmg l/20th volume of a solution containing lOnM membrane-bound TF After further mcubation for 1 hr, FX was added to 190 nM At appropriate times, aliquots were removed and the reaction quenched with an equal volume of 50 mM EDTA Activated FXa in quenched samples was then quantified using SPECTROZYME™-FXa as chromogenic substrate Figure 6 depicts the inhibition of TF-FVIIa by a representative hybπd molecule KDTF5 (*), a soluble K165A, K166A TF mutant (hTFAA) (■), and TF7I-C, a Kunitz-type senne protease inhibitor (•) for TF-FVIIa Values were determmed in a modified FX activation assay, performed with 2-fold more concentrated FVIIa and membrane-TF, and with varying inhibitor concentrations K * determinations were made by fitting the fractional rate vs inhibitor concentration data to equation 1 (infra) Figure 7 depicts the effects of TF-FVIIa mhibitors on the clottmg tune determmed in a prothrombin (PT) time assay Coagulation was initiated by mixmg citrated human plasma containmg inhibitor with an equal volume of a solution containing membrane-bound TF (mTF) and CaCl 2 Fold-prolongation of clottmg time was defined as the clottmg tune in the presence of inhibitor divided by the clotting time its absence (PBS control) This latter time was 53 2 ± 2 7 seconds Data are shown for KDTF5 ('), TF7I-C (•), hTFAA (■) and an equimolar mixture of TF7I-C and hTFAA (») Figure 8 depicts the effects of TF-FVIIa inhibitors on the clotting time determmed in an activated partial thromboplastm time (APTT) assay The sample (citrated human plasma and inhibitor) and activator (Intrumentation Laboratories Cephahn + Activator APTT Reagent) were incubated together for 70 seconds at 37 °C, then CaCl 2 was added and the clotting time was determined Fold prolongation of clotting time was defined as the clottmg time in the presence ofthe mdicated concentration of inhibitor divided by the clotting time in the absence of inhibitor This latter time was 63 7 ± 9 0 seconds Data are shown for KDTF5 ( » ), TF7I-C (•), hTFAA (■), and equimolar mixture of TF7I-C and hTFAA (*) Detailed Descnption of the Preferred Embodiments Definitions Abbreviations used throughout the descπption mclude FD(a for Factor IXa, FXIa for Factor Xla, FXa for Factor Xa, TF for tissue factor, FVII for zymogen factor VII, FVIIa for Factor Vila, TF-FVIIa for tissue factor-Factor Vila complex, FVIT/FVIla for FVII and or FVIIa, BPTI for basic pancreatic trypsin inhibitor, APPI for the Kunitz protease inhibitor domam of Alzheimer's amyloid β- protein precursor inhibitor (Hynes et al , (1990) supra) -(Gly) 4 -Ser-, and G 4 S for a 5 ammo acid polypeptide havmg the ammo acid sequence Glv-Gly- Gly-Gly-Ser, TFPI for tissue factor pathway inhibitor, K,* for apparent equilibrium dissociation constant, PT for prothrombm time, APTT for activated partial thromboplastm time A TF-FVIIa mediated or associated process or event, or equivalently, an activity associated with plasma FVIIa, accordmg to the present invention is any event which requires the presence of TF-FVIIa The general mechanism of blood clot formation is reviewed by Ganong, in Review of Medical Physiology, 13th ed , Lange, Lost Altos CA, pp41 1-414 (1987) Coagulation requires the confluence of two processes, the production of thrombm which induces platelet aggregation and the formation of fibrin which renders the platelet plug stable As outl ed in Figure 1, the process compnses several stages each requinng the presence of discrete proenzymes and procofactors The process ends fibrin crosslinking and thrombus formation Fibrinogen is converted to fibrin by the action of thrombm Thrombm, turn, is formed by the proteolytic cleavage of prothrombm This proteolysis is effected by FXa which binds to the surface of activated platelets and in the presence of FVa and calcium cleaves protJirombm TF-FVIIa is required for the proteolytic activation of FX by the extnnsic pathway of coagulation Therefore, a process mediated by or associated with TF-FVIIa, or an activity associated with FVIIa mcludes any step in the coagulation cascade from the formation ofthe TF-FVII complex to the formation of a fibπn platelet clot and which initially requires the presence TF-FVIIa For example, the TF-FVIIa complex mitiates the extnnsic pathway by activation of FX to FXa, FIX to FIXa, and additional FVII to FVIIa TF-FVIIa mediated or associated process, or FVIIa activity, can be conveniently measured employing standard assays such as those described in Roy, S , (1991) J Biol Chem 266 4665-4668, and O'Brien, D , et al . (1988) J Clin Invest 82 206-212 for the conversion of Factor X to Factor Xa in the presence of Factor VII and other necessary reagents A TF-FVIIa related disease or disorder is meant to include chronic thromboembolic diseases or disorders associated with fibrin formation mcludmg vascular disorders such as deep venous thrombosis, arterial thrombosis, stroke, tumor metastasis, thrombolysis, artenosclerosis and restenosis following angioplasty, acute and chronic indications such as inflammation, septic shock, septicemia, hypotension adult respiratory distress syndrome (ARDS), disseminated intravascular coagulapathy (DIC) and other diseases The TF-FVIIa related disorder is not limited to . vivo coagulopathic disorders such as those named above but includes ex. vivo TF- FVIIa related processes such as coagulation that may result from the extracoφoreal circulation of blood mcludmg blood removed in-line from a patient in such processes as dialysis procedures, blood filtration, or blood bypass during surgery The terms "tissue factor protein" and "wild type tissue factor" are used to refer to a polypeptide having an ammo acid sequence correspondmg to a naturally occurring mammalian tissue factor or a recombmant tissue factor havmg an ammo acid sequence of a naturally occurring tissue factor which is capable of inducing blood coagulation through its interaction with plasma FVII/FVIIa Naturally occurring TF includes human species as well as other animal species such as rabbit, rat, porcme, non human primate, equine, murine, and ovine tissue factor The ammo acid sequence of the mammalian tissue factor proteins are generally known or obtainable through conventional techniques The human sequence as well as the number given to the ammo acids are those descnbed by Momssey, J H , et al , (1987) 50.129 "hTFAA" and "K165A K166AsTF" referto a soluble tissue factor protem vanant havmg the ammo acid sequence of human TF as described above from amino acid 1 to ammo acid 219 and wherem the naturally occurring Lys ammo acids at positions 165 and 166 are replaced with Ala residues By "substitution" of any ammo acid is meant that an ammo acid ofthe wild-type tissue factor has been replaced by chemical or enzymatic or other appropnate means with a moiety other than a wild-type ammo acid The terms "Kunitz-type serme protease inhibitor domam," "Kunitz-type domam," "Kunitz domam," "KD" and the like are used interchangeably herem to refer to an approximately 58 amino acid residue polypeptide charactenzed by a conservation of cysteme residues with the senne protease inhibitor BPTI (bovine pancreatic trypsin inhibitor, Creighton and Charles, (1987) Cold Spring Harbor Symp Quant Biol 52 51 1-519) first isolated in crystallme form m 1936 (Kunitz, M , and Northop, J H , (1936) J Gen Physiol 19 991-1007) Kunitz domams share cysteme residue placement, tertiary folding, and structural characteristics A family of proteins has been identified contammg one, two or three Kunitz domams The family includes LACI ( poprotem-associated coagulation inhibitor, also TFPI Broze, Jr G J , et al , ( 1990) Biochemistry 29 7539- 7546), APPI (Alzheimer's amyloid β-protem precursor, Hynes, T R , (1990) Biochemistry 29 10018-10022), the α-3 chain of human type VI collagen (see WO 93/141 19) and inter- α -trypsin inhibitor (Hochstrasser, K , E , (1985) Biol Chem Hoppe-Seyler 366 473) Kunitz domains contain six specifically spaced cyste es that are present naturally in disulfide bonds (Bode, W , and Huber, R , (1992) Eur J Biochem 204 433-451) The three disulfide bridges stabilize the protem and are partially responsible for the overall 3-dιmensιonal folding characteristic of a Kunitz domam In the 58 residue Kunitz type seπne protease BPTI and APPI, cystemes are present at residues 5, 14, 30, 38, 51, and 55 The removal of a one disulfide bridge, however is not accompanied by a large structural change (Eigenbrot, C , et al , (1990) Protem Eng 3 591-598 The crystal structure of Kunitz domam type serine protease inhibitors has been determined for BPTI and APPI (Hynes, T R , et al , (1990) Biochem , 29 10018-10022) A central anti-parallel three-stranded β-sheet and a C-terminal α-helix form the core ofthe domam (Bode, W , and Huber, R , supra) The segments ofthe core domam form the supportmg scaffold for the exposed primary bmdmg loop ofthe properly folded protein (the "pπmary binding loop" as defined hereιn)(Bode. W , and Huber, R , supra) A secondarv binding loop participates along with the pnmary bmdmg loop to define the interface between the Kunitz domain and the cognate protease target (Ruhlman, A , et al , (1973) J Mol Biol 77 417-436) The "pnmar} binding loop" of a Kunitz domam is designated by Pyf^ '^2'^ l'^ \ '^2 '^3 '^4 (residues 1 1-19 APPI) The term "Pi" is used herein to refer to the position preceding the scissile peptide bond ofthe seπne protease inhibitors as previously defined Similarly, the term "P j "' is used to refer to the position followmg the scissile peptide bond ofthe inhibitor Increasing numbers refer to the next consecutive position pieced g (e g , P 2 and P 3 ) and following (e g , P 2 and P the scissile bond The residue numbering corresponds to that of BPTI such that residue 15 is at the P j position The term "active site" and the like when used herein with reference to FVIIa refer to the catalytic and zymogen substrate bmdmg site, mcludmg the "S j " site of FVIIa as that term is defined by Schecter, 1 , and Berger, A , (1967) Biochem Biophys Res Commun 27 157-162 The term "ammo acid" withm the scope ofthe present invention is meant to refer to naturally occurring L alpha ammo acids or residues The commonly used one and three letter abbreviations for ammo acids are used herein (Lehninger, A L , Biochemistry, 2d ed , pp 71-92, (1975), Worth Publishers, New York) Modes for Carrying out the Invention The hybπd molecules ofthe present mvention compπse at least two distmct domams Each molecule of the present mvention contains a Factor Vila active site inhibitor domain which binds to the active site of FVII/FVIIa and a tissue factor domam which bmds to FVII/FVIIa through protein-protem interactions at the cofactor bmdmg site According to the present mvention the active site mhibitor domain is linked to the N- terminus ofthe tissue factor domam, preferably via a flexible amino acid linker domam 1 Tissue Factor Domam The tissue factor domam ofthe compositions ofthe present mvention is a tissue factor protein variant which by virtue of, for example, an ammo acid substitution, msertion, or deletion in the ammo acid sequence of a mammalian tissue factor protein, or by virtue of glycosylation variation including deglycosvlated or unglycosylated tissue factor molecules, is capable of neutralizing the ability of tissue factor to induce blood coagulation while retaining at least its ability to bind to Factor Vll/Vlla In a particular embodiment the TF domam in complex with FVIIa has a decreased ability to catalyze the conversion of substrate Factor X to Factor Xa product Thus, the tissue factor domam ofthe present mvention is believed to, without limitation, compete with wild-type tissue factor for the cofactor binding site of Factor Vll/VIIa, thereby neutralizing or preventing wild type tissue factor from actmg as a cofactor in the coagulation cascade The tissue factor domam ofthe present mvention is capable of inhibiting or neutralizing any available tissue factor protein from inducing blood coagulation through the extπnsic coagulation pathway (see, Bach, R , (1988) CRC Cnt Rev Biochem 23 339-368) As will be appreciated by the skilled artisan the term ' neutralize" is a relative term Thus the term "neutralize" when used to describe the biological activity ofthe tissue factor domam ofthe present mvention means a tissue factor protem vaπant that when added in a 10-fold molar excess to wild-type tissue factor in a standard chromogenic assay (see, Roy, S , (1991) J Biol Chem 266 4665-4668, and O'Bπen, D , et al (1988) J Clm Invest 82 206-212) produces at least a 50% inhibition of the conversion of Factor X to Factor Xa the presence of Factor VII and other necessary reagents Preferably the tissue factor domain will produce at least a 50% inhibition at a 5-fold molar excess and more preferably at least a 50% inhibition at a 2-fold molar excess In a more preferred embodiment the tissue factor domain of the present invention will produce at least a 50% inhibition ofthe conversion of Factor X to Factor Xa when present in a 1 1 stoichiometric ratio with wild type tissue factor protein According to the present mvention TF domams include but are not limited to full length, phosho pid associated tissue factor domains having both a transmembrane domain and a cytoplasmic domain as well as TF domams wherem all or a portion of the transmembrane and/or cytoplasmic domain of wild type tissue factor have been deleted Accordingly, in determining the biological activity of a TF domam ofthe present mvention in a chromogenic assay as described the wild-type tissue factor corresponds m type to the particular TF domam bemg tested Therefore a full length TF domam compnsmg all or a portion ofthe transmembrane domam of wild-type tissue factor and associated with a phospholipid is tested in a biological assay with wild type TF of the corresponding type comprising all or a portion ofthe transmembrane domam in a similar phospholipid environment Likewise, a soluble TF domam wherein the transmembrane and cytoplasmic domain have been deleted is assayed with a wild-type TF domain wherein the transmembrane and cytoplasmic domam have been deleted It is a characteristic of the TF domam of the present invention that the protem bind FVII/FVIIa Accordingly, the TF domam of the present mvention shares those residues with wild type TF protein that are necessary for the bmdmg of TF to FVII/FVIIa By "bind to FVII/FVIIa" is meant that the TF domain ofthe present invention has the ability to bind to FVII/FVIIa to a degree that TF domam can compete for bindmg with wild type TF at physiological concentrations Preferred among the TF domams are those that have a KD for FVII FVIIa of about between 10 0 picomolar (pM) and about 1 micromolar (μM) in a standard bmdmg assay such as that described by Kelley et al , (1995) supra More preferably the TF domam has a KD for FVII/FVIIa of about between 10 pM and 10 nano olar (nM) and most preferably about between 10 pM and 1 nM The skilled artisan will recognize those residues in TF that contribute to the FVIIa binding (Kelley et al (1995) supra. Gibbs et al , (1994) supra. Ruf et al , (1994) Biochemistry 33, 1565- 1572 Schullek et al (1994) J Biol Chem 269 19399-19403, Muller et al , (1994) 33 10864-10869) According to the present invention, the TF domam shares at least those residues with wild type TF which are required for FVIIa/FVII bmdmg, as descnbed Preferably, the tissue factor domam will share at least about 80% sequence homology and more preferably between about 85%-95% sequence homology with wild-type tissue factor protein TF domams include but are not limited to full length, membrane bound or phoshohpid associated tissue factor domams having both a transmembrane domam and a cytoplasmic domam The TF domain also includes tissue factor domams wherein all or a portion of the transmembrane and/or cytoplasmic domain of wild type tissue factor have been deleted Accordingly, the tissue factor domam of the molecule can be formulated as soluble protein having the carboxy 1-termmal membrane anchor portion and cytoplasmic portion removed Alternatively, a TF protem can be prepared as an mtegral membrane protem having a membrane anchor The tissue factor domain having a complete membrane anchor domam is provided association with phospholipid compositions such as liposome formulations Preferred among the TF domams ofthe present mvention are those TF domains wherem all or a portion ofthe transmembrane and cytoplasmic domams of wild type tissue factor have been deleted Accordmg to this aspect ofthe present mvention, the TF domam compnses at least a portion ofthe N-terminal fibronectin type III domam of wild type tissue factor Preferably, the TF domam compnses at least ammo acids 1 - 102 of wild type tissue factor More preferably the TF domain of the present invention comprises both fibronectin type III domams of wild type tissue factor Preferably, accordmg to this aspect ofthe present invention, at least ammo acids 1-219 of wild type TF are present The TF domain of the present invention comprises a polypeptide which retains its ability to b d FVII/FVIIa and which is further capable of neutralizing the procoagulant activity of wild type tissue factor as descnbed above By way of illustration, substitution, msertion or deletions of particular amino acids along the length of wild type TF produce TF variants with reduced ability to act as a cofactor for FVIIa The skilled artisan will recognize those residues of wild type TF which contribute to the procoagulant function of TF For example, residues m the area of ammo acids 157-168 contnbute to the procoagulant function of TF-FVIIa (Kelley et al , (1995) supra. Ruf et al , (1992) supra') but are not important for FVII/FVIIa binding Accordmg to the present invention any or all of these ammo acids are selectively substituted or deleted to provide a TF domam that binds to FVII/FVIIa but is capable of neutralizing the procoagulant activity of wild type tissue factor In a preferred embodiment, any or all of residues Tφl58, Lysl59, Serl63, Glyl64, Lysl65, Lysl66, and Tyr 185 of wild type tissue factor are selectively substituted or deleted to provide a TF domam ofthe present mvenuon Preferred substitutions are descnbed in U S Patent No 5,346,991 and include substitution with an ammo acid other than one beaπng a substantially positively charged side cham at physiological pH Exemplary substitutions mclude any or all ofTφl58Phe, Lysl59Ala, Serl63Ala, Lysl65Ala, Lysl66Ala, and Tyrl 85Ala In a most preferred aspect of the present mvention, lysme residues 165 and 166 which are important to TF cofactor function but do not interfere with FVIIa complex formation (Roy et al , (1991) J Biol Chem 266 22063, Ruf et al , (1992) J Biol Chem 267 6375) are selectively substituted Therefore, according to a preferred aspect ofthe present mvention at least residues 165 and 166 of wild type tissue factor are selectively substituted to result in a molecule which retains its ability to b d FVII/FVIIa but has a reduced ability to act as a cofactor as described In a particular aspect, alanine substitution of these residues is preferred although any substitution which results in a decreased rate of FX activation catalyzed by the TF-FVIIa complex (Ruf et al , ( 1992) supra) is appropnate Lys e residues 165 and 166 are located on the C-terminal fibronectin type III domam of TF on the opposite surface of the molecule from residues found to be important for FVIIa bindmg on the basis of mutagenesis results (Kelley et al , (1995) supra) Preferred tissue factor domams of the present invention are those described m U S Patent No 5,346,991 , entitled "Tissue Factor Mutants Useful for the Treatment of Myocardial Infarction and Coagulopathic Disorders" the disclosure of which is specifically incoφorated herein by reference This patent describes the generation of tissue factor vaπants that are capable of inhibiting the ability of endogenous tissue factor to induce coagulation These variants have either or both of the positively charged ammo acid residues 165 and 166 substituted with an α-amino acid other than one bearing a substantially positively charged side chain at physiological pH The vaπants mclude human tissue factor molecules as descnbed above havmg the cvtoplasmic portion of wild type tissue factor, residues 244-263, removed, as well as the transmembrane region at residues 220-243 Any of the tissue factor variants may appropriately form the TF domain of the present invention International Publication No WO 94/28017 also descπbes TF vaπants that are able to bind FVII/FVIIa and have a reduced procoagulant cofactor activity Most prefeπed among the molecules described therein are a tissue factor protem havmg an ammo acid sequence homologous to a wild type tissue factor protem and wherem at least one ammo acid associated with TF cofactor function is selectively substituted, deleted or replaced to result in a molecule which retains its ability to bmd FVII/FVIIa but which has reduced ability to act as a cofactor as descnbed above 2 Active Site Domain According to the present invention the "active site inhibitor domam" of the compositions may be selected from any one of several groups of Factor Vila active site directed inhibitors Such active site inhibitors are broadly categonzed for the puφose ofthe present mvention mto l) active site inhibitors which reversibly bmd the active site of FVIIa and are cleavable by Factor Vila, n) active site mhibitors which reversibly bind to the active site of Factor Vila but cannot be cleaved, and in) active site inhibitor molecules which irreversibly bind to the active site of Factor Vila For a review of inhibitors of senne proteinases see, Proteinase Inhibitors (Research Monographs m Cell and Tissue Physiology, v 12) Elsevier Science Publishing Co , Inc , New York (1990) Accordmg to the first group, active site inhibitor domams which reversibly bind to and are cleavable by the active site of Factor Vila, the Kunitz and Kazal type serine protease inhibitors are preferred with the Kunitz type bemg most preferred Reversible active site inhibitor domains bmd to the active site of Factor Vila through non-covalent interactions such as ionic bonds, hydrophobic interactions or hydrogen bondmg Kunitz domams are recognized by the skilled artisan to be slow tight bmdmg reversible inhibitors of serine proteases Kunitz domam active site inhibitor domains of the present mvention mclude any of the known mammalian Kunitz type domains and especially the Kunitz domain APPI (from human Alzheimer's disease amyloid β-protein precursor, Castro, M et al (1990) FEBS Lett 267 207-212) residues 1-58, TFPI-KD1 (residues 22-79), TFPI-KD2 (residues 93-150), and TFPI-KD3 (residues 185-242) of human TFPI (tissue factor protem inhibitor or LACI, Broze Jr , G J et al , (1990) Biochemistry 29 7539-7546), ITI-KD1 and ITI-KD2, (residues 22-79 and 78-135) of human inter- α -trypsin inhibitor, respectively (Vetr, H et al , (1989) FEBS Lett 245 137-140), Collagen α 3 (VI) (residues 2899-2956) Collagen alpha 3 (VI) cham precursor (Chu, M L (1990) et al EMBO J 9 385-393), HKIB9 (7-60) Human Kunitz-type protease inhibitor, HKIB9 ( oms, K , m Genbank Database (Dec 31 , 1993, Release 39 0), submitted Jan 19,1994), BPTI (1-58), Aprotinin, bovine basic pancreatic trypsin inhibitor (Creighton T E and Charles, I G , (1987) Cold Sprmg Harbor Symp Quant Biol 52 51 1-519) Preferred among the Kunitz-type senne proteases are those molecules which bmd FVIIa active site with sufficient affinity to reversibly inhibit the molecule By this is meant that the Kunitz-type domam is able to bmd to and inhibit the catalytic activity of FVIIa as measured by routme assays such as those descnbed (below) Such molecules have an apparent dissociation constant (K,*) with respect to TF-FVIIa of less than about 100 nM more preferably the molecules have an apparent dissociation constant of less than about 10 nM Most preferred among the Kunitz type domains are those that have a K * of less than about 5 nM for TF-Factor Vila Apparent equilibrium dissociation constants (K,*) are determined using methods derived for tight- bmd g inhibitors (Bieth. J , (1974) Proteinase Inhibitors 463-469 Williams, J W and Morrison J F , (1979) Methods Enzymol 63 437-467), assuming enzyme and inhibitor form a reversible complex with a 1 1 stoichiometry as has been observed for the interaction of Kunitz-type domain with the FVIIa serine protease (Bode, W and R Huber, (1992) Eur J Biochem 204 433-451, Laskowski, M , Jr and I Kato, (1980) Annu Rev Biochem 49 593-626) The data are fit by nonlinear regression analysis to Equation 1 _ χ [E ZI +K -J ( [E ZI ÷K *) ~ (4 - [E • [IJ ) (1) V /v 2 - lE where V,/V 0 is the fractional activity (steady-state inhibited rate divided by the unmhibited rate), [EJ is the total FVIIa concentration and [I Q ] is the total inhibitor concentration By way of example and not limitation, preferred Kunitz type domams have a 58 ammo acid backbone structure, with ammo acids 11-19 correspondmg to primary bindmg loop which fits into the active site of the senne protease Kunitz-type domams havmg a particular ammo acid sequence withm the primary binding loop demonstrate preferred inhibition as defined above Exemplary Kunitz domams showing the preferred inhibition of factor VTla as descnbed above are Kunitz type domams with a Pro at position P5, a Gly at position P4, a Pro, Val, Leu, or Tφ at position P3, a Cys at position P2, an Arg, Lys, or Met at position Pl, an Ala at position Pl', a Leu Met or Ile at position P2', a Met, Ile, Leu or Tyr at position P3', and Leu, Lys or Arg at position P4' Kunitz type domains also preferred accordmg to the present invention also feature Phe, Val, Ile, Tφ or Tyr at position 34 (P19') a Cys at position 38 (P23') and a His, Tyr, or Gly at position 39 (P24') Exemplary Kunitz type active site inhibitor domains are also descnbed International Publication No WO 95/23860 and are represented by structural formula I R,-P5-P4-P3-P2-P 1 -Pr-P2 , -P3'-P4 , -R 2 -P19'-R 3 -P23'-P24 , -R 4 Accordmg to this formula, when P5-P4', P19', P23', and P24' are selected as described above, R ( is selected from APPI amino acids 1-10, VREVCSEQAE (SEQ ID NO 1), TFPI-KD1 amino acids 22-31 , MHSFCAFKAD (SEQ ID NO 2), TFPI-KD2 ammo acids 93-102, KPDFCFLEED (SEQ ID NO 3), TFPI-KD3 amino acids 185-194, GPSWCLTPAD (SEQ ID NO 4), ITI-KD1 ammo acids 22-31, KEDSCQLGYS (SEQ ID NO 5), ITI-KD2 ammo acids 78-87, TVAACNLPIV (SEQ ID NO 6), HKIB9 amino acids 1-10, LPNVCAFPME (SEQ ID NO 7), and BPTI ammo acids 1-10, RPDFCLEPPY (SEQ ID NO 8) R 2 is selected from APPI ammo acids 20-33, RWYFDVTEGKCAPF (SEQ ID NO 9), TFP1-KD1 ammo acids 41-54, RFFFNIFTRQCEEF (SEQ ID NO 10), TFPI-KD2 ammo acids 1 12-125, RYFYNNQTKQCERF (SEQ ID NO 11), TFPI-KD3 ammo acids 204-217, RFYYNSVIGKCRPF (SEQ ID NO 12), ITI-KD 1 amino acids 41-54, RYFYNGTSMACETF (SEQ ID NO 13), ITI-KD2 amino acids 97-1 10, LWAFDAVKGKCVLF (SEQ ID NO 14), Collagen α 3(VI) ammo acids 2918-2931, KWYYDPNTKSCARF (SEQ ID NO 15), HK1B9 ammo acids 20-33, RWFFNFETGECELF (SEQ ID NO 16), and BPTI ammo acids 20-33, RYFYNAKAGLCQTF (SEQ ID NO 17) R 3 is selected from the group YGG and YSG R 4 is selected from the group APPI ammo acids 40-58 (Met52Ala), GNRNNFDTEEYCAAVCGSA (SEQ ID NO 18), APPI amino acids 40-58, GNRNNFDTEEYCMAVCGSA (SEQ ID NO 19), TFPI-KD1 amino acids 61-79, GNQNRFESLEECKKMCTRD (SEQ ID NO 20), TFPI-KD2 amino acids 132-150, GNMNNFETLEECKNICEDG (SEQ ID NO 21), TFPI-KD3 ammo acids 224-242, GNENNFTSKQECLRACKKG (SEQ ID NO 22), ITI-KD1 ammo acids 61-79, GNGNNFVTEKECLQTCRTV (SEQ ID NO 23), ITI-KD2 ammo acids 117-135, GNGNKFYSEKECREYCGVP (SEQ ID NO 24), Collagen α 3(VI) ammo acids 2938-2956, GNENKFGSQKECEKVCAPV (SEQ ID NO 25), HK1B9 ammo acids 40-58, GNSNNFLRKEKCEKFCKFT(SEQ ID NO 26), and BPTI amino acids 40-58, AKRNNFKSAEDCMRTCGGA (SEQ ID NO 27), In a preferred Kunitz type active site inhibitor domain Ri has the sequence VREVCSEQAE (SEQ ID NO 1 ) R 2 has the sequence RWYFDVTEGKCAPF (SEQ ID NO 9) R 3 has the sequence YGG, and R 4 has the sequence GNRNNFDTEEYCAAVCGSA (SEQ ID NO 18) or GNRNNFDTEEYCMAVCGSA (SEQ ID NO 19) Therefore, preferred Kunitz type active site mhibitor domams include 1-18 R,PGVCRALILR 2 FR 3 CGR 4 (SEQ ID NO 28) 1-49 R,PGWCRALILR 2 FR 3 CGR 4 (SEQ ID NO 29 1-14 R j PGFCRALILR 2 FR 3 CGR 4 (SEQ ID NO 30 1-16 R,GGWCRALILR 2 FR 3 CGR 4 (SEQ ID NO 31 where R 4 is the sequence identified by SEQ ID NO 19, and 11-4 R j PGPCRAMISR 2 FR 3 CYR 4 (SEQ ID NO 32 II-3 R,PGWCRAMISR 2 IR 3 CGR 4 (SEQ ID NO 33 II-6 R j PGPCKAMISR 2 IR 3 CWR 4 (SEQ ID NO 34 111-27 R j TGPCRALISR- j WR j C -H^ (SEQ ID NO 35 111-30 R,TGPCRALISR 2 YR 3 CGR 4 (SEQ ID NO 36 TF7I-VY R,PGVCRALILR 2 FR 3 CYR 4 (SEQ ID NO 37 TF7I-LY R,PGLCRALILR 2 FR 3 CYR 4 (SEQ ID NO 38 TF7I-WY R,PGWCRALILR 2 FR 3 CYR 4 (SEQ ID NO 39 TF7I-PG R 1 PGPCRALILR 2 FR 3 CGR 4 (SEQ ID NO 40 IV-47C R,PGPCRAMMKR 2 IR 3 CHR 4 (SEQ ID NO 41 IV-54C R,PGPCRALMKR 2 VR 3 CYR 4 (SEQ ID NO 42 IV-31B R,PGPCRALMKR 2 VR 3 CFR 4 (SEQ ID NO 43 IV-49C R,PGPCRAMMKR 2 IR 3 CYR 4 (SEQ ID NO 44 IV-50C R,PGPCRAMYKR 2 IR 3 CYR 4 (SEQ ID NO 45 IV-57C R,PGVCRAMMKR 2 IR 3 CGR 4 (SEQ ID NO 46 IV-51C R,PGPCKALMRR 2 YR 3 CYR 4 (SEQ ID NO 47 IV-35B R,PGPCKAIMKR 2 IR 3 CHR 4 (SEQ ID NO 48 IV-58C R,PGPCKALMKR 2 YR 3 CHR 4 (SEQ ID NO 49 IV-48C R,PGPCKALMKR 2 WR 3 CWR 4 (SEQ ID NO 50 IV-46C R,PGPCKAMIKR 2 LR 3 CYR 4 (SEQ ID NO 51) IV-55C R,PGPCKALMKR 2 FR 3 CYR 4 (SEQ ID NO 52) IV-32B R,PGPCKALMKR 2 YR 3 CYR 4 (SEQ ID NO 53) IV-36B R,PGPCKALMKR 2 VR 3 CYR 4 (SEQ ID NO 54) IV-40B R,PGACKAMYKR 2 IR 3 CGR 4 (SEQ ID NO 55) 53b R,PGPGRALILR 2 FR 3 AYR 4 (SEQ ID NO 56), and TF7I-C R,PGPCRALILR 2 FR 3 CYR 4 (SEQ ID NO 57) where R 4 has the sequence identified by SEQ ID NO 18 It will be appreciated by the skilled artisan that with a Kunitz type active site inhibitor domain all or a portion of the Kunitz type domain may be used as the active site inhibitor domain accordmg to the present mvention Any portion ofthe Kunitz domam which binds with sufficient affinity to reversibly inhibit FVIIa will be sufficient as Factor Vila active site domam Such molecules generally comprise at least the P j and P j ' residues ofthe Kunitz domam and preferably the pπmary bmdmg loop of the Kunitz domam P 5 through P 4 ' The active site mhibitor moiety of the present invention may also be an irreversible FVIIa serine protease inhibitor Such irreversible active site inhibitor domams generally form covalent bonds with the Factor Vila active site Such irreversible inhibitors mclude general seπne protease inhibitors such as peptide chloromethylketones (see, Williams et al , (1989) J Biol Chem 264 7536-7540) or peptidyl chloromethanes, azapeptides, acylating agents such as various guanidmobenzoate derivatives and the 3-alkoxy-4- chloroisocoumanns, sulphonyl fluorides such as phenylmethylsulfonylflouπde (PMSF), diisopropylflourophophate (DFP), tosylpropylchloromethyl ketone (TPCK) and tosyllysylchloromethlyketone (TLCK), nitrophenylsulphonates and related compounds, heterocydic protease inhibitors such as isocoumarins, and coumaπns 3 Linker Accordmg to the present mvention. the tissue factor domain is linked, preferably via its N-terminus to the FVII FVIIa active site inhibitor domain of the hybrid molecule via a flexible linker domain The linker component ofthe hybπd molecule ofthe invention does not necessarily participate m the bmdmg ofthe molecule to FVII FVIIa Therefore, accordmg to the present mvention, the l ker domam, is any group of molecules that provides a spatial bndge between the FVII/FVIIa active site inhibitor domam and the tissue factor domain ofthe molecule The linker domam can be of vanable length and makeup, however, accordmg to the present invention, it is the length ofthe linker domam and not its structure that is important The linker domam preferably allows for the active site domam ofthe hybnd molecule to fit mto the seπne protease active site groove of FVII FVIIa while allowing the tissue factor domain of the molecule to bmd to the TF bmdmg site on the FVII/FVIIa molecule Therefore, the length ofthe linker domain is dependent upon the character ofthe two "functional" domams ofthe hybrid molecule One skilled in the art will recognize that various combinations of atoms provide for variable length molecules based upon known distances between various bonds (Morrison, and Boyd, Organic Chemistry, 3rd Ed, AUyn and Bacon, Inc , Boston, MA (1977)) For example, the linker domain may be a polypeptide of vaπable length The ammo acid composinon ofthe polypeptide determines the character and length ofthe linker In a preferred embodiment, the linker molecule comprises a flexible, hydrophilic polypeptide cham Exemplary linker domams comprises one or more [(Gly) -Ser] units In a preferred aspect, the active site inhibitor domain is a Kunitz t pe senne protease inhibitor the TF domain is hTFAA and the lmker domain is a polypeptide comprising between 5 and about 35 ammo acids and spanning a distance of greater than about 30A More preferably, the lmker comprises between about 20 and about 30 am o acids and spans a distance of greater than about 6θA Most preferably the linker comprises about a 22 to 27 ammo acid polypeptide and is comprised of about 4 to 5 [(Gly) 4 -Ser] units 4 Synthesis The hybnd molecules ofthe present mvention may be synthesized by vanous techniques which are well known in the art These include recombinant DNA techniques, solid phase synthesis, solution phase synthesis, organic chemical synthetic techniques or a combmation of these techniques The choice of synthesis will depend upon the particular molecule to be generated For example, in one embodiment the hybπd molecule of the present mvention is not entirely "protein" in nature and is synthesized by a combination of recombinant techniques and solution phase techniques For example, for the synthesis of hybπd molecules ofthe present invention which contain both ammo acid or protem portions and non-protein portions the molecule is generally obtamed by synthesizing the protem portion ofthe molecule by recombinant techniques as described below followed by coupl g the non protem portion of the molecule to the protein portion via solid phase or solution phase methods For the couplmg of protem and non protein portions ofthe molecule, chemical coupling is preferred Accordmg to this procedure, traditional crosslinking agents are employed such as molecules havmg one or more reactive groups that can react with more than one sites on the protem and non-protein molecules Biocompatable crosslmkers are preferred havmg the characteristics of being non-carcmogenic, nontoxic, and substantially nonimmunogenic m vivo Typically the cross linker will covalently bond with an amino group or a sulfhydr l group on the protem portion of the molecule and a hydroxyl, ammo, aldehyde or carboxylic acid group ofthe non-protein portion ofthe molecule Methods of crosslinking molecules are reviewed by Means and Feaney (1990) Bioconjugate Chemistry, 1 2-12 Vanous techniques are available which may be employed to produce DNA, which can encode proteins for the recombinant synthesis of hybrid protems of the mvention For mstance, it is possible to derive DNA based on naturally occumng DNA sequences that encode for changes m an ammo acid sequence ofthe resultant protem These mutant DNA can be linked together and used to obtam the hybrid molecules of the present mvention These techniques contemplate, m simplified form, obtaining a gene encoding a tissue factor domam and a gene encoding an active site inhibitor domam such as a Kunitz type domam of structural formula I, modifying the genes by recombinant techniques such as those discussed below inserting the genes into an appropriate expression vector separated by a gene encoding a linker module of various lengths inserting the vector into an appropriate host cell, culturing the host cell to cause expression of the hybrid molecule, and purifying the molecule produced thereby Somewhat more particularly, a DNA sequence encoding the bifunctional molecule of the present mvention is obtained by synthetic construction of the DNA sequence (Sambrook J et al Molecular Cloning (2nd ed ), Cold Spring Harbor Laboratory, N Y , (1989) Bv way of example, expression vectors encoding wild type tissue factor can be obtained and subject to site specific mutagenesis (Kunkel et al , (1991) Methods Enzymol 204 125-139, Carter, P et al (1986) Nucl Acids Res 13 4331 , Zoller, M J et al , (1982) Nucl Acids Res 10 6487), cassette mutagenesis (Wells, J A , et al ( 1985) Gene 34 315), or restriction selection mutagenesis (Wells J A et al , (1986) Philos Trans, R Soc London Ser A 317, 415) to obtain the tissue factor domam ofthe molecule The mutant DNA can then be used bv insertion into expression vectors contammg DNA encodmg an active site inhibitor domam A DNA sequence encoding a linker domam of varying length such as one or more [(Gly) 4 -Ser] units can then be inserted into the same expression vector Ohgonucleotide-mediated mutagenesis is a preferred method for prepaπng the DNA encodmg the tissue factor vaπants and the Kunitz type active site inhibitor domams ofthe present mvention This technique is well known m the art as descnbed by Adelman et al , (1983) DNA. 2 183 Briefly, the native or unaltered DNA of a wild type tissue factor or Kunitz type domam for mstance APPI, is altered by hybridizing an oligonucleotide encodmg the desired mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteπophage contammg the unaltered or native DNA sequence The DNA encodmg vaπants are then inserted mto an appropnate plasmid or vector separated by DNA sequence encoding a linker domam The vector is used to transform a host cell In general, plasmid vectors contammg replication and control sequences which are derived from species compatible with the host cell are used connection with those hosts The vector ordinanly carnes a replication site, as well as sequences which encode proteins that are capable of providing phenotypic selection in transformed cells For example, E colt may be transformed usmg pBR322, a plasmid derived from an E colt species (Mandel, M et al , (1970) J Mol Biol 53 154) Plasmid pBR322 contams genes for ampicillin and tetracycline resistance, and thus provides easy means for selection Other vectors mclude different features such as different promoters which are often important in expression For example, plasmids pKK223-3 pDR720 and pPL- lambda represent expression vectors with the tac, tφ, or P L promoters that are currently available (Pharmacia Biotechnology) Other preferred vectors can be constructed usmg standard techniques by combining the relevant traits ofthe vectors described herein Relevant traits ofthe vector mclude the promoter, the ribosome bindmg site, the vanant gene or gene fusion, the signal sequence, the antibiotic resistance markers, the copy number and the appropnate origins of replication In E coli, Kunitz domams have been expressed as intact secreted proteins (Castro, M et al , (1990) FEBS Lett 267 207-212), lntracellularly expressed proteins (Altman, J D et al , (1991 ) Protem Eng 4 593- 600), or as fusion proteins (Sinha, S et al , (1991) J Biol Chem 266 21011-21013, Lauritzen, C et al , (1991 ) Prot Express Punf 2 372-378, Auerswald, E A et al , (1988) Biol Chem Hoppe-Seyler 369 27-35) The host cell may be prokaryotic or eukaryotic Prokaryotes are preferred for clon g and expressing DNA sequences to produce parent polypeptides, segment substituted polypeptides, residue-substituted polypeptides and polypeptide variants For example, E coli K12 strain 294 (ATCC No 31446) may be used as £ co B, E coli X1776 (ATCC No 31537), and £ coli c600 and cόOOhfl, £ coli W31 10 (F-, gamma- prototrophic /ATCC No 27325), bacilli such as Bacillus subtilis and other enterobacteπaceae such as Salmonella -typhimurium or Serratia marcesans and vanous pseudomonas species The preferred prokaryote is E coli W3110 (ATCC 27325) When expressed by prokaryotes the polypeptides typically contain an N- terminal methionine or a formyl methionine and are not glycosylated These examples are, of course intended to be illustrative rather than limiting In addition to prokaryotes, eukaryotic organisms, such as yeast cultures, or cells derived from multicellular organisms may be used In principle, any such cell culture is workable However, terest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a reproducible procedure (Tissue Culture. Academic Press. Kruse and Patterson, eds [1973]) Examples of such useful host cell lines are VERO and HeLa cells, Chinese Hamster Ovary (CHO) cell lines, W138, 293, BHK, COS-7 and MDCK cell lines Yeast expression systems have been used to make Kunitz domams (Wagner, S L et al , (1992) Biochem Biophys Res Commun 186 1138-1 145, Vedvick, T et al , (1991) J Indust Microbiol 7 197-202) In particular the yeast Pichia pastons has been used successfully usmg the Saccharomyces cerevisiae α matmg factor prepro signal sequence and the P pastons alcohol oxidase AOX1 promoter and terminator sequences Other yeast expression vectors and hosts commonly used to express heterologous proteins are also contemplated 5 Compositions The hybnd molecule ofthe present mvention compnsmg a TF domain and a FVIIa active site domain is typically provided m a compositional form that is suitable for its intended use The hybπd molecule of the present invention compnsmg a TF domam can be prepared in the soluble form such as the hTFAA form descnbed herem Accordmg to this aspect ofthe mvention the tissue factor domam ofthe molecule is prepared without a membrane anchor Alternatively, the tissue factor domam can be prepared as a full-length membrane- associated form, with the membrane anchor present The hybrid molecule of the present invention may also comprise a TF domain comprising all or a portion of the transmembrane domam of wild type tissue factor It is preferred, accordmg to the present mvention, that bifunctional molecules compnsmg a TF domain contammg a membrane anchor domain be formulated in a composition compnsmg a mild detergent or phospholipid (PL) Although the composition of the present mvention compnsmg a full-length TF domain including a membrane anchor or transmembrane domain retam their biological activity they are preferably formulated in a phospholipid composition International Publication No WO 94/28017 descπbes the preparation of phospholipid compositions compnsmg a TF domain that are appropriate for the compositions of the present invention Preferred compositions described in WO 94/28017 and suitable for the pharmaceutical compostions ofthe present mvention are phospholipid compositions which afford maximum stability and biological activity for the composition Such phospholipid compositions are preferably formulated to form liposome compositions, as are generally well known the art As descnbed, suitable phospholipids for use in the liposome compositions ofthe present invention mclude those which contain fatty acids having twelve to twenty carbon atoms, said fatty acids may be either saturated or unsaturated Preferred phospholipids for use according to the present invention include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG) and phosphatidylseπne (PS) These phopho pids may come from any natural source and the phospholipids as such, may be compnsed of molecules with differing fatty acids Phospholipid mixtures compnsmg phospholipids from different sources may be used For example, PC, PG and PE may be obtained from egg yolk, PS may be obtamed from animal brain and spinal chord These phospholipids may come from synthetic sources as well The phospholipids are conveniently combmed in the appropnate ratios to provide the phospholipid mixture for use in prepaπng the composition ofthe present mvention The preparation of liposomes is generally well known and has been previously described Exemplary methods for preparation of liposomes mcludes reverse loadmg of liposomes (see U S Pat No 5, 104,661), or m the manner descnbed for the incoφoration of amphotencin B mto lipid vesicles (See, e g , Lopez-Berenstein et al , (1985) J Infect Dis , 151 704-710, Lopez-Berenstein, (1987) Aπtimicrob Agents Chemother 31 675- 678, Lopez-Berenstein et al , (1984) J Infect Dis , 150 278-283, and Mehta et al , (1984) Biochem Biophys Acta, 770 230-234) Liposomes with enhanced circulation time may also be prepared as described in U S Pat No 5,013,556 Thus, in one embodiment, the present invention contemplates the preparation of the hybπd molecules in the form of liposomes having TF domam portion of the molecule associated with the lipid bilayer of the liposomes, such that the TF membrane anchor domam is inserted through the lipid bilayer Other suitable compositions ofthe present mvention compπse any ofthe above noted compositions with a pharmaceutically acceptable earner, the nature ofthe carrier differing with the mode of administration, for example, in oral administration, usually using a solid carrier and in I V administration a liquid salt solution earner The compositions ofthe present invention mclude pharmaceutically acceptable components that are compatible with the subject and the protem ofthe invention These generally mclude suspensions, solutions and elixirs, and most especially biological buffers, such as phosphate buffered saline, saline, Dulbecco's Media, and the like Aerosols may also be used, or carriers such as starches, sugars, microcrystallme cellulose, diluents, granulating agents, lubneants, binders disintegrating agents, and the like (m the case of oral solid preparations such as powders, capsules, and tablets) As used herein, the term "pharmaceutically acceptable" generally means approved by a regulatory agency of the Federal or a state government or listed m the U S Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly humans The formulation of choice can be accomplished usmg a vanety ofthe aforementioned buffers, or even excipients mcludmg, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like "PEGylation" of the compositions may be achieved using techniques known to the art (see for example International Patent Publication No W092/16555, U S Patent No 5,122,614 to Enzon, and International Patent Publication No WO92/00748) Oral compositions may be taken in the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders 6 Therapeutic methods The bifunctional molecules ofthe present mvention can be used therapeutically to prevent the biological activity ofthe TF-FVIIa complex The inhibition of TF-FVIIa is desirable in indications where the reduction of TF-FVIIa dependent coagulation is implicated These situations mclude but are not limited to the prevention of arterial rethrombosis in combmation with thrombolytic therapy It has been suggested that the TF-FVIIa plays a significant role m a variety of clinical states mcludmg deep venous thrombosis, arterial thrombosis, stroke DIC, septic shock, cardiopulmonary bypass surgery, adult respiratory distress syndrome hereditary angioedema Inhibitors of TF-FVIIa may therefore play important roles m the regulation of inflammatory and/or thrombotic disorders Thus the present mvention encompass a method for preventmg TF-FVIIa mediated event in a human compnsmg administering to a patient m need thereof a therapeutically effective amount ofthe hybrid molecule ofthe present mvention A therapeutically effective amount ofthe hybrid molecule ofthe present invention is predetermined to achieve the desired effect The amount to be employed therapeutically will vary depending upon therapeutic objectives, the routes of administration and the condition being treated Accordingly, the dosages to be administered are sufficient to bmd to available FVII FVIIa and form an inactive complex leadmg to decreased coagulation in the subject bemg treated The therapeutic effectiveness is measured by an improvement in one or more symptoms associated with the TF-FVIIa dependant coagulation Such therapeutically effective dosages can be determmed by the skilled artisan and will vary depending upon the age condition, sex and condition ofthe subject bemg treated Suitable dosage ranges for systemic admmistration are typically between about 1 μg/kg to up to 100 mg kg or more and depend upon the route of admmistration Accordmg to the present mvention a preferred therapeutic dosage is between about 1 μg/kg body weight and about 5 mg kg body weight For example, suitable regimens include intravenous injection or infusion sufficient to mamtam concentration in the blood in the ranges specified for the therapy contemplated Pharmaceutical compositions which comprise the polypeptides ofthe invention may be administered in any suitable manner, including parental, topical, oral, or local (such as aerosol or transdermal) or any combination thereof Suitable regimens also include an initial admmistration by intravenous bolus injection followed by repeated doses at one or more intervals Where the composition ofthe mvention is bemg administered in combmation with a thrombolytic agent, for example, for the prevention of reformation of an accludmg thrombus in the course of thrombolytic therapy, a therapeutically effective dosage ofthe thrombolytic is between about 80 and 100 % ofthe conventional dosage range The conventional dosage range of a thrombolytic agent is the daily dosage used m therapy and is readily available to the treating physician (Physicians Desk Reference 1994, 50th Edition, Edward R Barnhart, publisher) The typical dosage range will depend upon the thrombolytic being employed and include for tissue plasmmogen activator (t-PA), 0 5 to about 5 mg/kg body weight, streptokmase, 140,000 to 2,500,0000 units per patient urokmase, 500,000 to 6,250,00 units per patient, and anisolated streptokinase plasmmogen activator complex (ASPAC), 0 1 to about 10 units/ kg body weight The term combmation as used herem includes a single dosage form contammg at least the molecule of the present invention and at least one thrombolytic agent The term is aiso meant to mclude multiple dosage forms wherem the molecule ofthe present mvention is administered separately but concurrently by two separate admmistration, such as m sequential admmistration These combmations and compositions work to dissolve or prevent the formation of an occluding thrombus resultmg in dissolution of the occluding thrombus Accordmg to a further aspect ofthe mvention the hybnd molecule may be employed in preventing ex vivo coagulation such as that encountered the extracoφoreal perfusion of blood through for example artificial valves, prothesis, stents or catheters According to this aspect ofthe invention the extracoφoreal devise mav be coated with the compositions ofthe invention resulting a lower nsk of clot formation due to extrinsic pathway activation The followmg examples are offered by way of illustration and not by way of limitation The disclosures of all citations the specification are expressly mcoφorated herem by reference EXAMPLES Materials Human Factor Vila, Factor X, Factor Xa, were purchased from Haematologic Technologies Inc (Essex Jet , VT) Membrane tissue factor (mTF) was prepared by sonication of a human embryonic kidney cell line (293) expressmg recombinant, full length (residues 1-263) human TF (Paborsky, L R et al , ( 1990) Protein Engmeeπng 3 547-553) Bovine trypsin, 4-methylumbelhferyl p-guanidinobenzoate and CHAPS were purchased from Sigma Chemicals, Inc Bovme serum albumm (BSA), Fraction V was obtamed from Calbiochem (La Jolla, CA) N α -Benzoyl-L-argmme- -nιtroanιiιde was purchased from Bachem California (Torrance, CA) Human plasmin S-2302, S-2251 and S-2366 were purchased from Kabi Vitrum (Sweden) and SPECTROZYME™ FXa was purchased from Amencan Diagnostica (Greenwich, CT) and CHROMOZYM™ t-PA was from Boehrmger Mannheim All other reagents were of the highest grade commercially available Example 1 Construction and Expression of Fusion Proteins Plasmids encodmg tissue factor-Kunitz domain fusion protems were constructed from the plasmid pZTFAA (Kelley, R F et al , (1995) Biochemistry 34 10383-10392) designed for expression of hTFAA by secretion from E coli As shown Figure 3, the expression unit of pZTFAA has the stll signal sequence joined to the N-terminus of hTFAA and transcπption is dnven by the alkaline phosphatase promoter (phoA) pZTFAA also has elements necessary for replication of the plasmid in smgle or double stranded form The coding sequence for the TF7I-C Kunitz domam was excised from the plasmid pA4G32-TF7I-C (Dennis M S & Lazarus, R A J Biol Chem (1994) 269 22129-22136) by restπction enzyme digest with PstI and BamHI For construction of genes encodmg fusion protems with the Kunitz domam joined to the C-terminus of hTFAA a Sacll restπction enzyme site was introduced into pZTFAA by o gonucleotide-directed mutagenesis (Kunkel T A et al , Methods m Enzymology, (1987) 154 367-382) The resultmg plasmid was digested with Sacll and Sphl, and then ligated with the Pstl/BamHI fragment of the Kunitz domain and two oligonucleotide linkers prepared by chemical synthesis One lmker has Sacll/Pstl cohesive ends and encodes a smgle copy ofthe G 4 S module and was designed to fuse hTFAA in the correct reading frame with the N-terminus ofthe Kunitz domain The second linker has BamHI/SphI cohesive ends and supplies the stop codon ofthe construct For construction of fusion protem genes having a Kunitz domain attached to the N-terminus of hTFAA, pZTFAA was cleaved with Nsil which cuts the DNA at the junction between the stll and hTFAA segments The Nsil cut plasmid was ligated with the Pstl BamHI Kunitz domain fragment and two oligonucleotide linkers prepared by chemical synthesis One linker had Nsi PstI cohesive ends thus joining the Kunitz domain in frame with the stll signal sequence The second lmker has BamHI/Nsil cohesive ends, encodes a smgle G 4 S module, and joins the Kunitz domam in frame with the N-terminus of hTFAA The stop codon is denved from pZTFAA Fusion genes having multiple copies of the G 4 S module were constructed by inserting chemically synthesized oligonucleotides encodmg the (G S) n unit between the appropnate restriction enzyme sites in TFKD1 or KDTF I For TFKD1, the Sacll Pstl sites were used, and for KDTF 1 , the BamHI/Nsil sites were used All fusion genes were confirmed by dideoxynucleotide sequencmg (Sanger, F et al , PNAS(USA) (1977)74 5463-5467) Phagemids encodmg the fusion protems were transformed into £ coli strain 33B6, a derivative of £ coli W31 10, for expression Overnight saturated cultures were used to inoculate (1%) 10 L of media in a fermentation tank Fermentation was performed as described previously (Carter, P et al , Bio/Technology, (1992)10 163-167) except that the temperature was 30 °C rather than 37 °C Fusion protems were secreted mto the peπplasm by virtue of the stll signal sequence Cells were harvested by centrifugation 32 hours after inoculation and stored frozen at -20 °C Example 2 Purification of Fusion Proteins Fusion protems were extracted from £ colt cell paste and puπfied by lmmunoaffinity chromatography on an ann- TF monoclonal antibody (D3) column (Paborsky, L R et al , Biochemistry (1989) 28 8072-8077) as described for mutants of soluble tissue factor (Kelley, R F et al , (1995) Biochemistry 34 10383-10392) In some cases, a final size exclusion chromatography step, usmg a Superdex 75 (Pharmacia) column equilibrated with phosphate-buffered salme, was mcoφorated to purify fusion protem monomers from higher mass oligomers The course ofthe fusion protem purification was followed by SDS-PAGE as shown in Figure 4 This procedure yielded highly puπfied fusion protem Each purified sample was submitted for analysis on a Sciex API 3 mass spectrometer equipped with an articulated electrospray source to venfy that protem mass was consistent with the desired molecular composition Multiply charged ions of horse myogiobin (MW = 16,951 Da) were used for instrument calibration Results ofthe analysis by mass spectrometry are shown Table I and mdicate that the fusion proteins have the expected molecular composition Concentrations of the purified fusion protems were determmed by three methods (Table I) 1) Detection of hTFAA with the D3 annbody, 2) determmation of Kunitz domam by titration of trypsin, and 3) absorbance measurements to determine total protein concentration All three methods gave similar concentrations Taken together with the mass spectrometry data these results show that the fusion protems are intact and that both the Kunitz domam and TF domams are functional when present m the fusion protem The fusion protems tested are listed below in Table I using shorthand notation KDTFn or TFKDn, wherein n is an integer referring to the number of G 4 S linker units According to that notation TF refers to hTFAA KD refers to the TF7I-C Kunitz domam KD following TF (TFKD 1 ) refers to a fusion protem wherem the KD domam is linked at its N-terminus via the peptide linker to the C-terminus of hTFAA TF followmg KD (KDTF) refers to a fusion protem wherem the KD C-terminus is linked via the peptide linker to the N-terminus of the hTFAA Table I D3 binding- Trypsin Total Fusion based TF mhibition- protein Protein Mass Mass cone based KD cone Species Predicted Observed cone (A, 80 ) TF D1 31440 31446 ± 5 28 μM 29 μM 28 μM KDTF1 31511 31515 ± 5 74 μM 77 μM 76 μM KDTF2 31826 31829 ± 2 66 μM 64 μM 66 μM KDTF3 32142 32146 ± 4 36 μM 38 μM 36 μM KDTF4 32457 32456 + 3 37 μM 35 μM 31 μM KDTF5 32772 32774 ± 5 20 μM 17 μM 16 μM KDTF6 33087 33088 ± 4 28 μM 22 μM 39 μM KDTF7 33403 ND 33 μM 28 μM 47 μM TABLE 1 Characterizations of puπfied fusion proteins Predicted masses for fusion protems in their native disulfide-bonded conformations are shown in Column 2 Results of mass spectral analyses are shown m Column 3 Columns 4-6 are concentration determinations based on bindmg to D3 monoclonal antibody immobilized m a BIAcore™ flow cell (an assay for TF domam structural/functional lntegnty), trypsin inhibition (an assay for Kunitz domain structural/functional integπty), and absorbance at 280 nm (total protem), respectively, for representative preparations of each fusion protem ND = not determmed Example 3 Fusion proteins inhibit TF-FVHa-dependent factor X activation The relative potency ofthe fusion protems for inhibiting the catalytic function ofthe membrane tissue factor (mTF)-Factor Vila (mTF-FVIIa) complex was evaluated by usmg an assay of FX activation In this assay, FX is added to a solution of mTF-FVIIa and the rate of FXa formation is determmed by removing aliqouts at vanous times, quenching the reaction by addition of EDTA to chelate calcium, and then measuring the amount of FXa formed by using the FXa specific substrate SPECTROZYME™ FXa FXa cleavage of SPECTROZYME™ FXa does not require calcium Hydrolysis of SPECTROZYME™ FXa is monitored by absorbance measurements at 405 nM The rate may be used to calculate the FXa concentration by reference to a standard curve constructed with puπfied FXa FX activation assays were conducted in a microtiter format and absorbance changes were monitored on an SLT EAR340AT plate reader controlled by a Macmtosh llci computer equipped with DeltaSoftll software (Biometal cs) Nonlinear regression analysis was earned out usmg KaleidaGraph v3 01 (Synergy Software) Activation assavs used mTF FVIIa and FX at final concentrations of 500 pM 100 pM and 190 nM respectively, in a volume of 200 μL Inhibitor, if added, was present at a final concentration of 1 nM This solution also contained 50 mM Tπs-HCl pH 8, 150 M NaCl, and 5 M CaCl 2 The concentration of a stock solution of FVIIa was determmed by active site titration with a quantitated sample of TF7I-C and by using CHROMOZYM™ t-PA as the substrate for FVIIa The concentration of TF7I-C had been accurately determmed by titration with trypsin that had been active site-titrated usmg 4-methylumbellιferyi p- guantdmobenzoate (Jameson, G W et al , (1973) Biochem J 131 107-1 17) After a 1 h mcubation of 80 nM trypsin plus an aliquot of diluted inhibitor in 50 mM Tris, pH 8 0, 100 mM NaCl, 10 M CaCl 2 and 0 05 % TRITON™ X-100 at room temperature, 20 μl of 5 mM N-benzoyl-L-argmme- -nitroanilide was added to a totai volume of 150 μl The change in absorbance at 405 nm was then monitored The concentrations determined assumed a 1 1 stoichiometry of inhibitor with trypsin or FVIIa The concentration of mTF was then determined from me increase in the rate of CHROMOZYM™ t-PA hydrolysis upon addition to a solution ofthe active site quantitated FVIIa The concentration of FX and FXa was that supplied by the manufacturer In tests ofthe inhibitory properties ofthe fusion proteins FVIIa was incubated with the fusion protein for 1 hour at 37 °C pπor to addition of mTF After addmg mTF, incubation at 37 °C was continued for another hour before addmg the substrate FX Timing ofthe reaction began with substrate addition and 25 μL aliqouts were removed at vanous times and mixed with an equal volume of 50 mM EDTA The amount of FXa formed was measured by addmg Factor Xa buffer (10X = 02 M HEPES pH 74, 1 5 M NaCl, 025 M EDTA, 1 % PEG- 8000) to a final concentration of IX followed by 0 5 mM SPECTROZYME™ FXa The final volume for each time pomt was 200 μL and the rates of SPECTROZYME™ FXa hydrolysis were monitored by changes the absorbance at 405 nm and are reported in mOD/min The effect of I nM inhibitors on FX activation catalyzed by mTF-FVIIa is shown m Figure 5 At a 1 nM concentration of either TF7I-C or hTFAA alone, the rate of FXa generation is equivalent to that observed m the uninhibited control Fusion protems KDTF1 and TFKD1 also had little effect on the rate of FX activation In contrast, KDTF2 gave a slight inhibition of FX activation The extent of inhibition increased for fusion proteins with a longer linker and complete inhibition was observed with the KDTF5 fusion protein KDTF4 appeared to be equipotent with KDTF5 whereas KDTF6 and KDTF7 were slightly weaker inhibitors These data show that a potent inhibitor can be obtained by jommg the Kunitz domain and hTFAA domains with a linker of appropnate length The best linker m this series has 4 or 5 G 4 S modules corresponding to a polypeptide chain length, in extended conformation, of 45-60 A Example 4 Determination of Equilibrium Dissociation Constants The apparent equilibnum dissociation constant (K,*) for inhibition of FX activation was determined for hTFAA, TF7I-C and KDTF5 These expeπments were conducted as descnbed for Example 3 except that the FVIIa and mTF concentrations were 200 pM and 1 nM, respectively, and the inhibitor concentration was vaned A standard curve was constructed for SPECTROZYME™ FXa hydrolysis by purified FXa (Hematech) such that the observed rate of hydrolysis for each time pomt could be converted mto a concentration of FXa generated These data were then analyzed by least squares Imear regression to calculate the initial velocity of FXa generation for each concentration of inhibitor Initial velocities were compared to the uninhibited rate to yield a fractional rate of FX activation for each mhibitor concentration These values are plotted in Figure 6 Nonlinear regression analysis by usmg equation 1 provided the K,* values of 160 ± 19 nM, 3 8 ± 0 5 nM, and 2 ± 6 pM for hTFAA, TF7I-C, and KDTF5, respectively It is clear that fusion of hTFAA and TF7I-C with a linker having an estimated length of 60 A increases the inhibitor potency by at least 100-fold Equation 1 V /v -i [E ° ] + [ I ° ] +κ ^ * ( [E ° 1 + [ I ° ] ^ *] 2 ~ ( 4 ' [E ° j ' [I ° n 0) 2 ' [E In this equation [E Q ] IS the enzyme concentration, [I n ] is the inhibitor concentration, V, is the initial velocity of FXa generation m the presence of [I 0 ] and V Q is the initial velocity in the absence of inhibitor Example 5 Coagulation Assays Clottmg times were measured using the ACL 300 Research Coagulation Analyzer For the prothrombm time (PT) assays, the mcubation time was set at 120 sec and acquisition time at 600 sec Membranes from 293 cells expressmg full length TF (Paborsky, L R et al , (1989)Bιochemιstry 28 8072-8077) were premixed with 25 mM CaCl 2 Citrated normal human plasma and inhibitor were mcubated together for at least 5 mmutes pπor to assay The sample (plasma and inhibitor) and reagent (CaCl 2 /TF) were automatically mixed together after a 2 mm mcubation at 37 °C The clotting time was determmed by optical assessment Fmal concentrations were 0 028 to 5 6 μM mhibitor, 0 5 nM mTF, 12 5 mM CaCl 2 , and 50% plasma m a total volume of 160 μL For the activated partial thromboplastm time (APTT) assays, the activation time was set at 70 sec and acquisition time at 360 sec Citrated normal human plasma and mhibitor were incubated together for at least 5 mmutes pπor to assay The sample (plasma and inhibitor) and activator (Instrumentation Laboratones Cephalm + Activator APTT Reagent) were automatically pipetted and mcubated together for 70 sec at 37 °C, then CaCl 2 was added and clottmg time determmed by means of optical assessment F al concentrations were 0028 to 5 6 μM inhibitor, 10 % activator, 10 0 mM CaCl 2 , and 50 0 % plasma in a total volume of 200 μL Results- The fusion protem KDTF5 gave a very potent inhibition of clotting in the PT assay as shown in Figure 7 KDTF5 was more potent than TF7I-C or hTFAA alone and also inhibited at a lower dose than observed for a mixture of TF7I-C and hTFAA With KDTF5 a 2-fold prolongation in clottmg time was obtamed at an mhibitor concentration of about 800 nM A 2-fold prolongation in clottmg time was obtamed at 1 9 μM for the equimolar mixture of TF7I-C and hTFAA A concentration of 4 μM hTFAA alone gave a 2-fold increase in clottmg time whereas a 2-fold prolongation was not obtained with TF7I-C at the highest concentration tested These data show that KDTF5 is a potent inhibitor of TF dependent clotting and has greater potency than the noncovalent mixture ofthe two inhibitors As shown in Figure 8, KDTF5 retained the effect on clotting time in an APTT assay previously observed for TF7I-C alone (Dennis, M S & Lazarus, R A J Biol Chem 269 22129-22136 [1994]) Both KDTF5 and the noncovalent mixture of TF71-C and hTFAA were slightly more potent that TF7I-C alone in inhibiting the intrinsic pathway of blood coagulation An inhibitor concentration of about 200 nM for either KDTF5 or the TF7I-C/hTFAA mixture gave a 2-fold prolongation in clottmg time A TF7I-C concentration of 400 nM was requued to give a 2-fold prolongation in clottmg time At the concentrations tested, hTFAA alone had no effect on the clottmg time determined in an APTT assay Example 6 Determination of antithrombotic potential in a rabbit model of deep medial injury Male New Zealand white rabbits (-4 kg) are anesthetized to surgical anesthesia plane with an IM injection of Ketamme / Xylaxme The rabbits are placed supine on a restraining board, warmed to 37 °C, and the neck and inner thigh area shaved Teflon catheters are placed in a margmal ear vein and femoral artery for drug delivery and sample collection respectively Pπor to treatment, blood samples are collected for coagulation tests (APTT and PT) Bleedmg time is assessed from a cut made the cuticle portion of a hind limb nail Incisions are made in the neck region and the entire left common carotid artery and its branches are surgically isolated An ultrasonic flow probe (Transonics®) is placed on the common carotid approximately 5 cm caudal to the common - internal bifurcation After blood flow reaches a stable baselme, drugs (salme or test compounds) are delivered via the margmal ear vem A deflated embolectomy catheter (Fogarty®, 3F) was then introduced mto the lumen ofthe common carotid via an incision m the lmgual branch Blood flow through the artery is stopped bπefly while the catheter is introduced and loosely secured with 2-0 silk tie at the incision site After the catheter is in place and secure, blood flow is restored The deflated balloon is advanced to within 2 mm ofthe flow probe and mflated with salme until resistance ofthe vessel wall is felt The catheter is pulled back with a steady motion to the first branch and then deflated This procedure is repeated several times for each experimental animal, after which the catheter is removed The ballooning procedure, from first msertion to removal ofthe catheter takes approximately 3 to 5 mmutes and results in an area of damage that is 1 5 to 2 cm length Over 40 mmutes, blood samples are taken for PT measurements, cuticle bleedmg times are assessed and blood flow through the carotid monitored Duration of patency is defined as the total amount of time (maximum = 40 minutes) that any measurable blood flow is detected in the artery Patency rate refers to the percentage of animals tested who had carotid artery blood flow ≥ 5 mmutes At the end ofthe experiment, the rabbit is euthanized and the carotid artery removed and opened If any thrombus is present, it is removed, blotted and the weight recorded SEQUENCE LISTING (1) GENERAL INFORMATION: (1) APPLICANT: Genentech, Inc. ( 11 ) TITLE OF INVENTION: Novel Factor Vila Inhibitors (in) NUMBER OF SEQUENCES: 57 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Genentech, Inc. (B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94080 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: WxnPatin (Genentech) (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNE /AGENT INFORMATION: (A) NAME: Kubmec, Jeffrey S. (B) REGISTRATION NUMBER: 36,575 (C) REFERENCE/DOCKET NUMBER: P0958BPCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415/225-8228 (B) TELEFAX: 415/952-9881 (C) TELEX: 910/371-7168 (2) INFORMATION FOR SEQ ID NO:l: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: Val Arg Glu Val Cys Ser Glu Gin Ala Glu 1 5 10 (2) INFORMATION FOR SEQ ID NO: 2: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Met His Ser Phe Cys Ala Phe Lys Ala Asp 1 5 10 (2) INFORMATION FOR SEQ ID NO: 3: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Lys Pro Asp Phe Cys Phe Leu Glu Glu Asp 1 5 10 (2) INFORMATION FOR SEQ ID NO: : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 ammo acαds (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: Gly Pro Ser Trp Cys Leu Thr Pro Ala Asp 1 5 10 (2) INFORMATION FOR SEQ ID NO: 5: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Lys Glu Asp Ser Cys Gin Leu Gly Tyr Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO: : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Thr Val Ala Ala Cys Asn Leu Pro Ile Val 1 5 10 (2) INFORMATION FOR SEQ ID NO:7: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 ammo acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Leu Pro Asn Val Cys Ala Phe Pro Met Glu 1 5 10 (2) INFORMATION FOR SEQ ID NO: 8: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 : Arg Pro Asp Phe Cys Leu Glu Pro Pro Tyr 1 5 10 (2) INFORMATION FOR SEQ ID NO: 9: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 10: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Arg Phe Phe Phe Asn lie Phe Thr Arg Gin Cys Glu Glu Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO:11: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Arg Tyr Phe Tyr Asn Asn Gin Thr Lys Gin Cys Glu Arg Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 12: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Arg Phe Tyr Tyr Asn Ser Val Ile Gly Lys Cys Arg Pro Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 13: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: Arg Tyr Phe Tyr Asn Gly Thr Ser Met Ala Cys Glu Thr Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 14: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (D) TOPOLOGY: Linear (Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Leu Trp Ala Phe Asp Ala Val Lys Gly Lys Cys Val Leu Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 15: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: Lys Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 16: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Arg Trp Phe Phe Asn Phe Glu Thr Gly Glu Cys Glu Leu Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 17: Arg Tyr Phe Tyr Asn Ala Lys Ala Gly Leu Cys Gin Thr Phe 1 5 10 14 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:18: Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr Cys Ala Ala Vai 1 5 10 15 Cys Gly Ser Ala 19 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr Cys Met Ala Val 1 5 10 15 Cys Gly Ser Ala 19 (2) INFORMATION FOR SEQ ID NO: 20: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 ammo acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: Gly Asn Gin Asn Arg Phe Glu Ser Leu Glu Glu Cys Lys Lys Met 1 5 10 15 Cys Thr Arg Asp 19 (2) INFORMATION FOR SEQ ID NO:21: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Gly Asn Met Asn Asn Phe Glu Thr Leu Glu Glu Cys Lys Asn Ile 1 5 10 15 Cys Glu Asp Gly 19 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: Gly Asn Glu Asn Asn Phe Thr Ser Lys Gin Glu Cys Leu Arg Ala 1 5 10 15 Cys Lys Lys Gly 19 (2) INFORMATION FOR SEQ ID NO: 23: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Gly Asn Gly Asn Asn Phe Val Thr Glu Lys Glu Cys Leu Gin Thr 1 5 10 15 Cys Arg Thr Val 19 (2) INFORMATION FOR SEQ ID NO: 24: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: Gly Asn Gly Asn Lys Phe Tyr Ser Glu Lys Glu Cys Arg Glu Tyr 1 5 10 15 Cys Gly Val Pro 19 (2) INFORMATION FOR SEQ ID NO:25: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Gly Asn Glu Asn Lys Phe Gly Ser Gin Lys Glu Cys Glu Lys Val 1 5 10 15 Cys Ala Pro Val 19 (2) INFORMATION FOR SEQ ID NO:26: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: Gly Asn Ser Asn Asn Phe Leu Arg Lys Glu Lys Cys Glu Lys Phe 1 5 10 15 Cys Lys Phe Thr 19 (2) INFORMATION FOR SEQ ID NO:27: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Ala Lys Arg Asn Asn Phe Lys Ser Ala Glu Asp Cys Met Arg Thr 1 5 10 15 Cys Gly Gly Ala 19 (2) INFORMATION FOR SEQ ID NO:28: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Val Cys Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 29: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Trp Cys Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO:30: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (x ) SEQUENCE DESCRIPTION: SEQ ID NO:30: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Phe Cys Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 ( 2 ) INFORMATION FOR SEQ ID NO: 31: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Gly Gly Trp Cys Arg 1 5 10 15 Ala Leu lie Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 32: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Met Ile Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Trp Cys Arg 1 5 10 15 Ala Met Ile Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 34: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala Met Ile Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys Trp Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO:35: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Thr Gly Pro Cys Arg 1 5 10 15 Ala Leu Ile Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Trp Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Thr Gly Pro Cys Arg 1 5 10 15 Ala Leu Ile Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Tyr Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO:37: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Val Cys Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 38: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Leu Cys Arg 1 5 10 15 Ala Leu Ile Ser Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 39: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 am o acids (B) TYPE: Ammo Ac d (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Trp Cys Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 40: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 41 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Met Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys His Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 42: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Val Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 43: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Val Tyr Gly Gly Cys Phe Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 45: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Met Tyr Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 46: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Val Cys Arg 1 5 10 15 Ala Met Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala ALa Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 7: ( l ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE. Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala Leu Met Arg Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Tyr Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO:48: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala lie Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys His Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Tyr Tyr Gly Gly Cys His Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids ( D ) TOPOLOGY : Linear ( xi ) SEQUENCE DESCRI PTION : SEQ I D NO : 50 : Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gl y Pro Cys Lys 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Va l Thr Glu Gl y Lys Cys 20 25 30 Ala Pro Phe Trp Tyr Gly Gly Cys Trp Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 51: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala Met Ile Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Leu Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (x ) SEQUENCE DESCRIPTION: SEQ ID NO:53: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Tyr Tyr Gly Gly Cys Tyr Gl y Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 54: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Lys 1 5 10 15 Ala Leu Met Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Val Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 55: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Ala Cys Lys 1 5 10 15 Ala Met Tyr Lys Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Ile Tyr Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO: 56: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Gly Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Ala Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58 (2) INFORMATION FOR SEQ ID NO:57: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 58 ammo acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: Val Arg Glu Val Cys Ser Glu Gin Ala Glu Pro Gly Pro Cys Arg 1 5 10 15 Ala Leu Ile Leu Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys 20 25 30 Ala Pro Phe Phe Tyr Gly Gly Cys Tyr Gly Asn Arg Asn Asn Phe 35 40 45 Asp Thr Glu Glu Tyr Cys Ala Ala Val Cys Gly Ser Ala 50 55 58

Claims: WHAT IS CLAIMED IS 1 A fusion protein comprising a) a Factor Vila ("FVIIa") active site inhibitor domain, b) a linker domain, and c) a tissue factor ("TF") domam 2 The fusion protem according to claim 1 wherein said FVIIa active site inhibitor domain is a reversible serine protease inhibitor 3 The fusion protein accordmg to claim 1 wherein said FVIIa active site inhibitor domain is an irreversible serine protease inhibitor 4 The fusion protem accordmg to claim 2 wherein said reversible serme protease inhibitor comprises a Kunitz domam ("KD") 5 The fusion protein of claim 4 wherein said linker domain comprises a -(Gly) 4 -Ser- linker module 6 The fusion protem of claim 5 wherein said lmker domain comprises four -(Gly)4-Ser- linker modules 7 The fusion protem of claim 5 wherem said linker domain comprises five -(Gly)4-Ser- linker modules 8 The fusion protem of claun 3 havmg the formula KD-[(Gly) 4 -Ser] χ -TF wherem KD is a Kunitz type active site inhibitor of Factor Vila, X is an integer between 1 and 10, and TF is tissue factor domam 9 The fusion protem of claim 8 wherem the tissue factor variant is hTFAA 10 The fusion protem of claim 9 wherem the KD is TF7I-C 11 The fusion protein of claun 10 wherem x is 4 12 The fusion protein of claim 10 wherein x is 5 13 A pharmaceutical composition compnsmg a pharmaceutically acceptable excipient and the fusion protem of claim 1 14 A method for inhibiting human Factor Vila (FVIIa) procoagulant activity comprising contacting said FVIIa with the fusion protem of claun 1 in an amount sufficient to inhibit the procoagulant activity of said TF-FVIIa 15 A method for inhibiting human tissue factor-Factor Vila (TF-FVIIa) procoagulant activity in a mammal comprising administering a therapeutically effective amount ofthe composition of claim 13 to the mammal 16 The method of Claun 15 further compnsmg administrating the composition in combmation with a thrombolytic agent 17 The method of Claun 15 further compnsmg administrating the composition in combination with an anticoagulant 18 A method of treating a mammal for which inhibiting Factor Vila is indicated compnsmg admmistermg a pharmaceutically effective amount ofthe composition of Claim 13 to the mammal 19 An isolated DNA molecule encoding the fusion protem of Claim 8 20 The DNA molecule of claim 19 further compnsmg an expression control sequence operably linked to the DNA molecule 21 An expression vector compnsmg the DNA molecule of claim 20 wherem the control sequence is recognized by a host cell transformed with the vector 22 The vector of claim 21 that is a plasmid 23 A host cell transformed with the plasmid of Claim 22 24 A method for expressmg a DNA molecule encodmg a senne protease mhibitor m a host cell, compnsmg culturmg the host cell of claim 23 under conditions suitable for expression of the inhibitor 25 The method of claim 24 further compnsmg recovering the inhibitor from the culture medium

Inventors: KELLEY ROBERT F, LAZARUS ROBERT A, LEE GEOFFREY F, KELLEY, ROBERT, F., LAZARUS, ROBERT, A., LEE, GEOFFREY, F.
Applicants: GENENTECH INC, GENENTECH, INC.
Application year: 1996
Main classification: C12N15
IPC codes: A61K38, C07K14, C12N1